Comparison of the Hologic Genius Digital Diagnostics System With the Liquid-based Cytology (LBC) Manual Microscopy

Sponsor
Hologic Deutschland GmbH (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04965857
Collaborator
(none)
3,000
1
16
187.9

Study Details

Study Description

Brief Summary

Quality assurance of the laboratory examinations. Prospective non-interventional study with ThinPrep slides collected during the German Co-Screening Program and routinely sent to the lab to prospectively evaluate the clinical performance of the Hologic Genius Digital Cytology (DC) system vs. the liquid-based cytology (LBC) manual microscopic approach

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Hologic's Genius Digital Diagnostics System

Detailed Description

The cause of cervical cancer is a persistent infection with high-risk types of human papillomavirus (HPV). Cytology has been the gold standard for cervical screening since the introduction of routine screening with the Pap test in the 1950s due to its effect on mortality in regions with screening programs. Since that time, there have been several technological advances (LBC, Imaging) to improve and automate cervical cytology, resulting in increased disease detection and efficiency. The Hologic's Genius Digital Diagnostics System is a CE-IVD (CE-marked in vitro diagnostic device) marked digital cytology platform. For quality assurance and to prospectively evaluate the Hologic Genius Digital Cytology (DC) system in the lab, selected routinely screened and already archived slides will be additionally reviewed with the liquid-based cytology (LBC) manual microscopic approach. Only anonymized results will be evaluated.

Study Design

Study Type:
Observational
Anticipated Enrollment :
3000 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Comparison of the Hologic Genius Digital Diagnostics System With the Liquid-based Cytology (LBC) Manual Microscopic Approach
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Slides from the German Co-Screening program

From 25,000 LBC slides (ThisPrep, Hologic Inc., USA) from the German Co-screening program evaluated using the Genius Digital cytology system all abnormal findings according to Munich III groups (II-p - V) and each 10th normal slide (Munich III group I and II) will be selected for the prospective evaluation by manual microscopy.

Diagnostic Test: Hologic's Genius Digital Diagnostics System
Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.

Outcome Measures

Primary Outcome Measures

  1. Sensitivity and specificity of detection of pre-cancerous lesions using Hologic Genius Digital Cytology Imaging scanner. [1 year]

    To demonstrate non-inferiority, the appropriate approximative one-sided 95% confidence interval for the true difference between the two approaches (Digital Cytology and Manual microscopic reading) will be constructed.

Secondary Outcome Measures

  1. To assess the rate of inadequate slides that cannot be read by the Hologic Genius Digital Cytology system. [1 year]

  2. Change in time needed to screen 80 slides using Hologic Genius Digital Cytology Imaging scanner. [1 year]

    To assess the impact on the workflow of the introduction of a Digital Cytology procedure to a high-throughput screening lab in Germany.

  3. Clinical performance of Hologic Genius Digital Cytology Imaging scanner using cells on a ThinPrep® slide. [1 year]

    The performance of Hologic Genius Digital Cytology Imaging scanner during cervical cancer screening (using histology as reference method) will be assessed via sensitivity, specificity, positive and negative predictive values.

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 90 Years
Sexes Eligible for Study:
Female
Inclusion Criteria:
  • LBC ThinPrep® samples are collected by gynaecologists and sent routinely to cytology laboratory Zotz & Klimas as part of the German Cervical cancer screening program.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zotz Klimas Partner für Diagnostik und Prävention MVZ Düsseldorf-Centrum Düsseldorf Germany 40210

Sponsors and Collaborators

  • Hologic Deutschland GmbH

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hologic Deutschland GmbH
ClinicalTrials.gov Identifier:
NCT04965857
Other Study ID Numbers:
  • BTS1650_20
First Posted:
Jul 16, 2021
Last Update Posted:
Apr 15, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 15, 2022